Digital pathology and AI are fundamentally transforming how biopharma companies discover, develop, and deliver life-changing medicines. As a result, today’s leaders aren’t debating whether to invest in digital pathology—they’re racing to scale it, unlocking faster breakthroughs, smarter clinical trials, and broader patient access to next-generation therapies.  

Organisations that move quickly are building defensible moats with proprietary data assets, AI-based precision diagnostics, and intelligent enterprise-wide workflows that competitors will struggle to replicate. 

In this exclusive Drug Discovery World webinar, leaders from Proscia, Amgen, Owkin and Nucleai will explore what the shift from analogue to computational pathology means for biopharma R&D leaders and how to position your organisation at the forefront of this transformation.

Key takeaways include: 

• Why the digital pathology tipping point is here—and accelerating
• How pathology AI is transforming the pace and precision of biopharma R&D
• Evidence-based pathology AI strategies leaders are implementing now to get ahead
• Strategic benefits aligned to priorities for therapeutic area leaders, digital transformation officers, translational science heads, and more
• Real-world success stories from organisations already gaining a competitive advantage
  
  Register for free and watch the webinar on-demand now!